In Cancer Diagnostics Profit Rests in Test Services

All the major reference labs in North America and Europe are also offering a slew of in-house developed diagnostic tests. This shift is leading to greater profits for those companies offering test services, according to a recent market report.

Test services are not a new business model. Myriad Genetics (Salt Lake City, UT, USA) was the first company, in the mid-1990s, to offer its patented and proprietary cancer assays as a service in its own laboratory, according to healthcare market research publisher Kalorama Information (New York, NY, USA). The first generation of these tests targeted small markets where the financial investment for the U.S. Food and Drug Administration (FDA) market clearance would be difficult to recuperate with a commercial test kit.

However, in the past few years many IVD companies have begun to establish current good manufacturing practice (cGMP)- and Clinical Laboratory Improvement Amendments (CLIA)-certified labs by which they offer their proprietary tests to physicians, hospitals, and reference labs. Nowhere is this trend more evident than in the commercialization of cancer diagnostics, according to Kalorama analysts.

In 2007, there were at least 40 company and lab developed cancer tests either already available or very near market. In 2008 and 2009, about 70 have been or are in development. The market for these tests is becoming very competitive. Reference labs such as LabCorp (Burlington, NC, USA), Quest Diagnostics (Madison, NJ, USA), Specialty Labs (Valencia, CA, USA), and Arup (London, UK), as well as numerous private pathology labs, now offer advanced genetic and proteomic tests that they have developed alone and in collaboration with IVD companies.

Growth rates demonstrate the results of this strategy, according to Kalorama. Median annual revenue growth from 2005 to 2009 for the major cancer-test service companies, including Clarient (Aliso Viejo, CA USA), Genomic Health (Redwood City, CA, USA), Genoptix (Carlsbad, CA, USA), and Myriad Genetics, was 60%; while average annual revenue growth was 14% for the major cancer diagnostics companies during the same period.

"Success in this new test commercialization model may appear like serendipity and a function of being in the right place at the right time,” noted Shara Rosen, Kalorama Information's diagnostic analyst. "While there is an element of this in success, it is more a question of successful product development; success is built on a test that fulfills a perceived unmet need, fulfills good test practices of sensitivity and specificity, and has an element of proprietary technology.”

Molecular biology is expected to lead to an exponential growth in the number of cancer tests available. Some 25,000 to 30,000 molecular and protein biomarkers may someday become part of the medical toolbox. The mix and match of molecular and protein markers opens the door to a whole new generation of tests, according to Kalorama. It is as part of this new generation of tests that company developed and in-lab developed cancer tests are aiming to make their mark.

Kalorama Information provides independent market research in the life sciences, as well as customized research services.

Related Links:
Kalorama Information